Brain-derived neurotrophic factor and the plasticity of the mesolimbic dopamine pathway.
Guillin
Oliver
O
Unité de Neurobiologie et Pharmacologie Moléculaire, INSERM U 573, Centre Paul Broca, 75014 Paris, France.
Griffon
Nathalie
N
Diaz
Jorge
J
Le Foll
Bernard
B
Bezard
Erwan
E
Gross
Christian
C
Lammers
Chris
C
Stark
Holger
H
Carroll
Patrick
P
Schwartz
Jean-Charles
JC
Sokoloff
Pierre
P
D000818:Animals; D019208:Brain-Derived Neurotrophic Factor / Q000502:physiology*; D003714:Denervation / Q000379:methods; D003863:Depression / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D015259:Dopamine Agents / Q000009:adverse effects; D018507:Gene Expression Regulation, Developmental; D006801:Humans; D007980:Levodopa / Q000009:adverse effects; D008032:Limbic System / Q000166:cytology / Q000254:growth & development / Q000378:metabolism*; D009473:Neuronal Plasticity / Q000502:physiology*; D017448:Receptors, Dopamine D2 / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D050637:Receptors, Dopamine D3; D012559:Schizophrenia / Q000378:metabolism; D013312:Stress, Physiological / Q000378:metabolism
D019208:Brain-Derived Neurotrophic Factor; C493593:DRD3 protein, human; D015259:Dopamine Agents; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; D007980:Levodopa; D004298:Dopamine